NCT01008995View on ClinicalTrials.gov

A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

322

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Psoriasis
Interventions
DRUG

placebo

Subcutaneous injection at Week 0 and 4

DRUG

ustekinumab

45 mg subcutaneous injection at Week 12 and 16

DRUG

placebo

Subcutaneous injection at Week 12

DRUG

ustekinumab

45 mg subcutaneous injection at Week 0, 4 and 16

Trial Locations (9)

Unknown

Beijing

Chongqing

Dalian

Guangzhou

Hangzhou

Nanjing

Shanghai

Shenyang

Xi'an

Sponsors

Lead Sponsor

Centocor, Inc.
All Listed Sponsors
lead

Centocor, Inc.

INDUSTRY